Executive Summary

Avastin may change the way the industry look upon antibody treatment of cancer in the same way Taxol changed the pharmaceutical companies' way of looking at possibilities in the field of cancer therapeutics.  

In "Antibodies as Cancer Therapeutics - R&D Situation & Business Perspectives -" BioSeeker Group has analyzed more than 300 industry related R&D projects evaluating antibody based cancer therapies. There are more than 50 companies focused on developing antibody based cancer treatments. With several approved monoclonal antibodies for at least 5 cancer indications and no less than 9 companies with projects that have reached phase III trials this field has evolved into a reality for cancer patients. Our aim has been to elucidate changes and progress in how antibodies are used for trying to cure cancer as well as describe the current and future business climate.  

Antibody therapy is a proven breakthrough for cancer treatment. However, obstacles still remain. The efficacy should and could be improved. More simple protocols are now being exchanged for more sophisticated ones, and novel solutions are continuing to emerge. The report also evaluates the latest advancements in antibody based cancer therapy as well as describes key company activities. BioSeeker Group is monitoring a large number of companies working in this field enabling highly updated analysis.

This 300-page report is a close to complete description of the ongoing efforts to develop innovative antibody strategies for the treatment of cancer. Sixty tables, graphs and figures help you to grasp the comprehensiveness of this field. Three different lagre appendixes summaries most of the commercial activities. The report identifies trends, describes and analyzes strategic shifts made by the industry. It also serves as a guide and a foundation for your needs of information structure. BioSeeker Group has structured the contents of this report into several well-defined concepts, such as MAbs directed against tumor antigens, anti-hormone antibodies, MAbs for receptor blocking and anti- angiogenesis, conjugated MAbs, and antibodies targeting CD-molecules. The comparison of therapeutic strategies, targets and cancer indications reveals differences between disease and treatment. 

Conference information from the latest meetings held by the American Society of Clinical Oncology, the American Association Cancer Research, the American Society of Hematology, and Oncology & Antibody Business Development Global Summit is also included in this extensive analysis. 

The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough succes. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way. One example is Rituxan, an antibody drug that has seen its revenue grow from $152 million in 1998 to more than $1 billion in 2002. Other antibody-based therapies that are close to or already on the market are Herceptin, Mylotarg, Zevalin, Bexxar, Campath, and Erbitux. 

If you are interested in the whole field of cancer immunotherapy, including antibody based strategies, the newly published BioSeeker report "A Shift in Cancer Immunotherapy Strategies" can strongly be recommended. In yet another coming report entitled "Immunotherapies Impact on the Cancer Market", BioSeeker Group will discuss late stage immunotherapy drugs and their effect on the market.

Size: 274 pages

Release date: Oct 28, 2003 

Publisher: BioSeeker 2003 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/BioSeeker_2003.html#a461